NRG
VKTX icon

Nemes Rush Group’s Viking Therapeutics VKTX Stock Holding History

Nemes Rush Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$270K Hold
300
– – 0.02% 193
2026
Q1 		$249K Hold
300
– – 0.02% 195
2025
Q4 		$315K Hold
300
– – 0.03% 174
2025
Q3 		$216K Buy
+300
New +$8.95K 0.02% 189

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Nemes Rush Group's VKTX Position: Q2 2026 in Review

Nemes Rush Group reduced its Viking Therapeutics (VKTX) stake by 0.06% in Q2 2026, selling an estimated $97 and leaving 5,165 shares worth $201K. The position accounts for 0.02% of the portfolio, ranked #215.

Nemes Rush Group first reported a position in VKTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $410K in Q3 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Nemes Rush Group held 5,165 shares of Viking Therapeutics worth $201K as of Q2 2026.
  • Nemes Rush Group sold 3 Viking Therapeutics shares in Q2 2026, an estimated $97.
  • Viking Therapeutics made up 0.02% of Nemes Rush Group's portfolio in Q2 2026, its #215 holding.
  • Nemes Rush Group first reported a position in Viking Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Nemes Rush Group's Viking Therapeutics position peaked at $410K in Q3 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Nemes Rush Group's 13F filing for Q2 2026, filed 14 Aug 2026.